Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HER2+
How do you approach HER2 directed therapy with discrepant results between FISH and Oncotype?
Especially if HER2 negative on pathological specimen
Answer from: Radiation Oncologist at Community Practice
At our institution, we don’t do Oncotype for HER2+ (by IHC or FISH) cases. See our published data showing the discrepancy.
Comments
Medical Oncologist at Stanford University, School of Medicine
Thank you so much for sharing this data!
Medical Oncologist at Joliet Oncology - Hematology Associates, Ltd.
What do you do if FISH is negative but oncotype is...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
This is a very rare event and we have not changed ...
3153
3158
3159
Sign in or Register to read more
7878
Related Questions
How do you reconcile data from the PATINA trial and DESTINY-Breast09 with respect to CDK4/6 inhibitor maintenance in metastatic ER+ HER2+ breast cancer?
What are your top takeaways in Medical Oncology from SABCS 2024?
What are your top takeaways in Breast Cancer from ASTRO 2024?
What adjuvant systemic therapy would you recommend for a premenopausal woman with a germline BRCA mutation who initially presented with locally advanced, HR+, HER2-negative (FISH) IDC, but was later found on surgical pathology to have HR+, HER2+ disease (IHC 3+) after neoadjuvant chemotherapy?
Is there evidence supporting the adjuvant use of neratinib in patients with high-risk, hormone receptor–positive, HER2-negative breast cancer that harbors an activating HER2 mutation?
What are your top takeaways in Breast Cancer from ESMO 2024?
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
How do you manage a patient with early stage HER2+ breast cancer patient who progressed on mastectomy after completing neoadjuvant TCHP?
In which breast cancer presentation would you consider earlier treatment with T-DXd, given the similar absolute PFS benefits seen with T-DXd in the DESTINY-Breast06 trial and DESTINY-Breast04 trials?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
Thank you so much for sharing this data!
What do you do if FISH is negative but oncotype is...
This is a very rare event and we have not changed ...